Bain Capital Life Sciences Investors, LLC

Person Signing this Report on Behalf of Reporting Manager:

Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP, (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general parter of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iv) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general parnter of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. The shares of common stock of Annexon, Inc. ("ANNX") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP and BCLS I Investco, LP on February 14, 2023 and reflect the exercise of securities exercisable for shares of ANNX common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding ANNX common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 3,601,926 shares of ANNX common stock. The shares of common stock of Savara Inc. ("SVRA") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on March 17, 2021 and reflect the exercise of securities exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 6,913,208 shares of SVRA common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Equity Opportunities, LP on February 14, 2023 and reflect the exercise of securities exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 1,082,404 shares of SYRS common stock. The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on Amendment No. 2 to the Schedule 13G filed by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP and BCLS I Investco, LP on February 14, 2023 and reflect the exercise of securities exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise. As of December 31, 2022, such persons held an aggregate of 11,590,336 shares of XFOR common stock.

Other Included Managers (11):